



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA

## ARCHIVIO ISTITUZIONALE DELLA RICERCA

### Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Joza, S., Hu, M.T., Jung, K., Kunz, D., Stefani, A., Dušek, P., et al. (2023). Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study. *BRAIN*, 146(8), 3258-3272 [10.1093/brain/awad072].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/955315> since: 2024-02-02

*Published:*

DOI: <http://doi.org/10.1093/brain/awad072>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

# 1 Progression of clinical markers in prodromal Parkinson's disease 2 and dementia with Lewy bodies: a multicentre study

3 Stephen Joza,<sup>1</sup> Michele T. Hu,<sup>2</sup> Ki-Young Jung,<sup>3</sup> Dieter Kunz,<sup>4</sup> Ambra Stefani,<sup>5</sup> Petr Dušek,<sup>6</sup>  
4 Michele Terzaghi,<sup>7,8</sup> Dario Arnaldi,<sup>9,10</sup> Aleksandar Videnovic,<sup>11</sup> Mya C. Schiess,<sup>12</sup> Wiebke  
5 Hermann,<sup>13</sup> Jee-Young Lee,<sup>14</sup> Luigi Ferini-Strambi,<sup>15</sup> Simon J. G. Lewis,<sup>16</sup> Laurène Leclair-  
6 Visonneau,<sup>17,18</sup> Wolfgang H. Oertel,<sup>19,20</sup> Elena Antelmi,<sup>21</sup> Friederike Sixel-Döring,<sup>19,22</sup> Valérie  
7 Cochen De Cock,<sup>23,24</sup> Claudio Liguori,<sup>25,26</sup> Jun Liu,<sup>27</sup> Federica Provini,<sup>28,29</sup> Monica Puligheddu,<sup>30</sup>  
8 Alessandra Nicoletti,<sup>31</sup> Claudio L. A. Bassetti,<sup>32</sup> Jitka Bušková,<sup>33</sup> Yves Dauvilliers,<sup>34</sup> Raffaele  
9 Ferri,<sup>35</sup> Jacques Y. Montplaisir,<sup>36,37</sup> Michael Lawton,<sup>38</sup> Han-Joon Kim,<sup>3</sup> Frederik Bes,<sup>4</sup> Birgit  
10 Högl,<sup>5</sup> Karel Šonka,<sup>6</sup> Giuseppe Fiamingo,<sup>7,8</sup> Pietro Mattioli,<sup>9</sup> Maria Lorena Lavadia,<sup>11</sup> Jessika  
11 Suescun,<sup>12</sup> Kyung Ah Woo,<sup>14</sup> Sara Marelli,<sup>15</sup> Kaylena Ehgoetz Martens,<sup>39</sup> Annette Janzen,<sup>19</sup>  
12 Giuseppe Plazzi,<sup>29,40</sup> Brit Mollenhauer,<sup>22,41</sup> Mariana Fernandes,<sup>25</sup> Yuanyuan Li,<sup>27</sup> Pietro  
13 Cortelli,<sup>28,29</sup> Michela Figorilli,<sup>30</sup> Calogero Edoardo Cicero,<sup>31</sup> Carolin Schaefer,<sup>32</sup> Lily Guiraud,<sup>34</sup>  
14 Giuseppe Lanza,<sup>35,42</sup> Jean-François Gagnon,<sup>36,37</sup> Jun-Sang Sunwoo,<sup>43</sup> Abubaker Ibrahim,<sup>5</sup> Nicola  
15 Girtler,<sup>9,10</sup> Claudia Trenkwalder,<sup>22,41</sup> Luca Baldelli,<sup>28,29</sup> Amelie Pelletier,<sup>1,36</sup> and Ronald B.  
16 Postuma<sup>1,36</sup> for the International REM Sleep Behavior Disorder Study Group

## 17 Abstract

18 The neurodegenerative synucleinopathies, including Parkinson's disease and dementia with  
19 Lewy bodies, are characterized by a typically lengthy prodromal period of progressive  
20 subclinical motor and non-motor manifestations. Among these, idiopathic REM sleep behavior  
21 disorder (iRBD) is a powerful early predictor of eventual phenoconversion, and therefore  
22 represents a critical opportunity to intervene with neuroprotective therapy. To inform the design  
23 of randomized trials, it is essential to study the natural progression of clinical markers during the  
24 prodromal stages of disease in order to establish optimal clinical endpoints.

25 In this study, we combined prospective follow-up data from 28 centers of the International REM  
26 Sleep Behavior Disorder Study Group representing 12 countries. Polysomnogram-confirmed  
27 REM sleep behavior disorder subjects were assessed for prodromal Parkinson's disease using the  
28 Movement Disorder Society criteria and underwent periodic structured sleep, motor, cognitive,

1 autonomic and olfactory testing. We used linear mixed-effect modelling to estimate annual rates  
2 of clinical marker progression stratified by disease subtype, including prodromal Parkinson's  
3 disease and prodromal dementia with Lewy bodies. In addition, we calculated sample size  
4 requirements to demonstrate slowing of progression under different anticipated treatment effects.

5 Overall, 1160 subjects were followed over an average of  $3.3 \pm 2.2$  years. Among clinical variables  
6 assessed continuously, motor variables tended to progress faster and required the lowest sample  
7 sizes, ranging from 151-560 per group (at 50% drug efficacy and 2-year follow-up). By contrast,  
8 cognitive, olfactory, and autonomic variables showed modest progression with higher variability,  
9 resulting in high sample sizes. The most efficient design was a time-to-event analysis using  
10 combined milestones of motor and cognitive decline, estimating 117 per group at 50% drug  
11 efficacy and 2-year trial duration. Finally, while phenoconverters showed overall greater  
12 progression than non-converters in motor, olfactory, cognitive, and certain autonomic markers,  
13 the only robust difference in progression between Parkinson's disease and dementia with Lewy  
14 bodies phenoconverters was in cognitive testing.

15 This large multicenter study demonstrates the evolution of motor and non-motor manifestations  
16 in prodromal synucleinopathy. These findings provide optimized clinical endpoints and sample  
17 size estimates to inform future neuroprotective trials.

18

19 **Author affiliations:**

20 1 Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada

21 2 Nuffield Department of Clinical Neurosciences, Division of Neurology and Oxford

22 Parkinson's Disease Centre, University of Oxford, UK

23 3 Department of Neurology, Seoul National University College of Medicine, Seoul National

24 University Hospital, Seoul, Republic of Korea

25 4 Clinic for Sleep & Chronomedicine, St. Hedwig-Krankenhaus, Berlin, Germany

26 5 Medical University Innsbruck, Department of Neurology, Innsbruck, Austria

27 6 Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine,

28 Charles University and General University Hospital, Prague, Czechia

- 1 7 Sleep Medicine and Epilepsy Unit, IRCCS Mondino Foundation, Pavia, Italy
- 2 8 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- 3 9 Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child  
4 Health (DINOEMI), Clinical Neurology, University of Genoa
- 5 10 IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 6 11 Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston,  
7 MA, USA
- 8 12 Department of Neurology, The University of Texas Health Science Center at Houston, Texas,  
9 USA
- 10 13 Department of Neurology, University of Rostock, Rostock, Germany
- 11 14 Department of Neurology, Seoul National University College of Medicine, Seoul  
12 Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South  
13 Korea
- 14 15 Sleep Disorders Center, Vita-Salute San Raffaele University, Milan, Italy
- 15 16 ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical  
16 Sciences, University of Sydney, Sydney, NSW, Australia
- 17 17 Department of Clinical Neurophysiology, CHU de Nantes, Nantes, France
- 18 18 Nantes Université, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases,  
19 Nantes, France
- 20 19 Department of Neurology and Section on Clinical Neuroscience, Philipps University  
21 Marburg, Marburg, Germany
- 22 20 Institute for Neurogenomics, Helmholtz Center for Health and Environment, München-  
23 Neuherberg, Germany
- 24 21 Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona,  
25 Verona, Italy
- 26 22 Paracelsus Elena Klinik, Centre for Movement Disorders, Kassel, Germany

1 23 EuroMov Digital Health in Motion, University of Montpellier, IMT Mines Ales, 34090  
2 Montpellier, France

3 24 Department of Neurology and Sleep, Beau Soleil Clinic, Montpellier, France

4 25 Sleep Medicine Center, Department of Systems Medicine, University of Rome Tor Vergata,  
5 Rome, Italy

6 26 Neurology Unit, University Hospital of Rome Tor Vergata, Rome, Italy

7 27 Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of  
8 Medicine, Shanghai, China

9 28 Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy

10 29 IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

11 30 Sleep Center, Department of Medical Sciences and Public Health, University of Cagliari,  
12 Cagliari, Italy

13 31 Department of Medical, Surgical Sciences and Advanced Technologies, GF Ingrassia,  
14 University of Catania, Catania, Italy

15 32 Department of Neurology, University Hospital Bern (Inselspital), 3010, Bern, Switzerland

16 33 National Institute of Mental Health, Klecany, Third Faculty of Medicine, Charles University,  
17 Prague, Czech Republic

18 34 Sleep Unit, Department of Neurology, Hôpital Gui de Chauliac, Montpellier, INSERM  
19 U1061, Montpellier, F-34093 Cedex 5 France

20 35 Clinical Neurophysiology Research Unit, Oasi Research Institute-IRCCS. Via Conte Ruggero  
21 73, 94018, Troina, Italy

22 36 Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal,  
23 Montréal, Canada

24 37 Department of Psychology, Université du Québec à Montréal, Montréal, Quebec, Canada

25 38 School of Social and Community Medicine, Bristol Medical School, University of Bristol,  
26 UK

1 39 Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo, Ontario,  
2 Canada

3 40 Department of Biomedical, Metabolic and Neural Sciences, University of Modena and  
4 Reggio-Emilia, Modena, Italy

5 41 Department of Neurosurgery, University Medical Center Goettingen, Göttingen, Germany

6 42 Department of Surgery and Medical-Surgical Specialties, University of Catania. Via Santa  
7 Sofia 78, 95123, Catania, Italy

8 43 Department of Neurology, Kangbuk Samsung Hospital, Seoul, Republic of Korea

9

10 Correspondence to: Ronald B. Postuma MD, MSc

11 Montreal General Hospital, 1650 Cedar Ave., H3G 1A4 Montreal, QC, Canada

12 E-mail: [ron.postuma@mcgill.ca](mailto:ron.postuma@mcgill.ca)

13 **Running title:** Progression in prodromal PD and DLB

14

15 **Keywords:** REM sleep behavior disorder; Parkinson's disease; dementia with Lewy bodies;  
16 prodromal stage; evolution

## 17 **Introduction**

18 Despite much promise, no therapeutic intervention has been able to alter the progression of the  
19 neurodegenerative synucleinopathies,<sup>1-3</sup> which include Parkinson's disease (PD), dementia with  
20 Lewy bodies (DLB), and multiple system atrophy (MSA). Aside from drug inefficacy, the lack  
21 of benefit could also reflect the possibility that the underlying neurodegenerative process has  
22 already progressed to a point beyond which no intervention would benefit. Therefore, targeting  
23 the prodromal stages of disease, when time still remains to prevent irreversible degeneration,  
24 could be the critical point at which to intervene.<sup>4</sup>

25

1 Synucleinopathies are distinctive for both a typically long prodromal period prior to  
2 phenoconversion to the overt stages of disease and for the involvement of multiple clinical  
3 domains, including motor and cognitive abnormalities, olfactory dysfunction, constipation,  
4 dysautonomia, and sleep disorders.<sup>5</sup> Among these, idiopathic REM sleep behavior disorder  
5 (iRBD), a parasomnia characterized by loss of REM atonia and consequent dream-enactment  
6 behavior, is common in all synucleinopathies.<sup>6</sup> It is also a powerful predictor of  
7 phenoconversion: the vast majority (>80%) of individuals with iRBD will ultimately develop an  
8 overt degenerative synucleinopathy, with a phenoconversion rate of approximately 6-8% per  
9 year.<sup>7,8</sup>

10  
11 iRBD subjects are therefore ideal candidates for neuroprotective trials. However, optimal  
12 endpoints to assess drug efficacy have yet to be established and are required to ensure that future  
13 trials are optimally designed. It is unclear to what degree different prodromal markers progress in  
14 the early stages of disease. Moreover, it remains to be established how a given clinical marker's  
15 progression is affected by disease subtype (e.g., prodromal PD vs. prodromal DLB)<sup>9</sup>.

16  
17 Although previous longitudinal multicenter studies have measured the degree to which clinical  
18 markers are predictive of phenoconversion in iRBD,<sup>7,8,10</sup> a systematic approach quantifying the  
19 progression of each marker over time has not been performed. Those studies that have  
20 longitudinally and systematically assessed marker progression in iRBD have been from single  
21 centers,<sup>9,11</sup> or required the use of expensive or sophisticated biomarker analyses that may not be  
22 suitable as primary outcome measures in Phase 3 trials.<sup>12,13</sup>

23  
24 In the present study, we combined the prospective results of 28 centers of the International RBD  
25 Study Group (IRBDSG) to: (i) assess the progression of clinical motor and non-motor markers in  
26 iRBD subjects over 5 years of follow-up; (ii) determine to what degree this progression differs  
27 depending on phenoconversion type; and (iii) calculate required sample sizes to inform the  
28 design of randomized neuroprotective trials for prodromal synucleinopathies.

# 1 **Materials and methods**

## 2 **Study subjects**

3 All study subjects had polysomnogram-confirmed iRBD according to standard criteria<sup>14</sup> and  
4 were without parkinsonism or dementia at baseline. Data were collected between 2003 – 2021,  
5 with the majority of subjects (80.0%) recruited after 2014 (**Supplementary Fig. 1**). Subjects  
6 were systematically assessed at baseline visit, and for inclusion, were required to have at least  
7 one follow-up examination. To reflect the situation of a clinical trial, in the primary analysis,  
8 subjects were required to meet MDS research criteria for probable prodromal PD, defined  
9 according to the criteria as having at least an 80% probability of prodromal Parkinson's disease<sup>5</sup>  
10 (using all information available at each center). For subjects that did not meet criteria at baseline  
11 but did in subsequent years (13.1% of all subjects), the baseline year was set to the first year in  
12 which criteria were met. Ethics approval was obtained from the local institutional boards of each  
13 center with subject consent in accordance with the Declaration of Helsinki.

## 14 **Study procedures**

15 Subjects underwent periodic structured sleep, motor, cognitive, autonomic, and olfactory testing  
16 on an approximately annual basis. For inclusion, we did not require that each marker was tested  
17 in each patient; rather, centers sent results for all markers that were systematically assessed  
18 (detailed in **Supplementary Table 1**). To be analyzed, each marker of interest needed to be  
19 systematically assessed by at least two centers and in at least 100 subjects at baseline. Markers  
20 included:

- 21 i. Standardized motor examination: tested with the MDS-UPDRS-III. For the primary  
22 analysis, we combined both the 2008 and 1987 versions of the UDPRS. When the  
23 1987 UPDRS-III was used (36% of subjects at baseline), scores were adjusted by  
24 multiplying by a weighting factor of 1.2<sup>15</sup>; an intercept term (i.e. the addition of 2.3)  
25 was not used since the calibration was originally developed for early PD, rather than  
26 prodromal PD, and would have lead to inaccurately inflated baseline MDS-UPDRS-  
27 III scores (e.g. a minimum score of 2.3 for a completely normal UPDRS-III).



- 1 ii. Standardized motor symptoms: MDS-UPDRS-II. If the 1987 UPDRS-II was used,  
2 scores were adjusted by multiplying by a weighting factor of 1.1 and adding an  
3 intercept of 0.2.<sup>15</sup>
- 4 iii. Standardized non-motor symptoms: MDS-UPDRS-I.
- 5 iv. Quantitative motor testing: Timed-up-and-go (TUG)<sup>16</sup> and Purdue Pegboard (scores  
6 reported are the 30 second task involving both hands).<sup>17</sup> Since one center (Houston)  
7 used a longer distance TUG (14 meters, rather than 6 meters), scores were  
8 additionally standardized to TUG velocity in meters per second (m/s) by dividing the  
9 distance of the task by time.
- 10 v. Olfaction: 40-item University of Pennsylvania Smell Identification Test (UPSIT), 12-  
11 item Cross-Cultural Smell Identification Test (CCSIT), or the 12- or 16-item Sniffin'  
12 Sticks (SS) tests. To harmonize results, z-scores were created for each test stratified  
13 by sex and/or age using published normatives and averaged.<sup>18-21</sup>
- 14 vi. Sleep: Epworth Sleepiness Scale (ESS),<sup>22</sup> Insomnia Severity Index (ISI),<sup>23</sup> Pittsburgh  
15 Sleep Quality Index (PSQI),<sup>24</sup> and the REM Sleep Behavior Disorder Screening  
16 Questionnaire (RBDSQ).<sup>25</sup>
- 17 vii. Office-based cognitive testing: Mini-Mental State Examination (MMSE)<sup>26</sup> and  
18 Montreal Cognitive Assessment (MoCA).<sup>27</sup>
- 19 viii. Autonomic symptoms: Scales for Outcomes in Parkinson's disease - Autonomic  
20 Dysfunction (SCOPA-AUT) scale.<sup>28</sup>
- 21 ix. Orthostatic blood pressure: assessed supine and after 1-3 minutes standing. Since the  
22 timing and number of standing measurements varied between centers, postural scores  
23 from 1-3 minutes were averaged together.
- 24 x. Psychiatric symptoms: Beck Depression Inventory,<sup>29</sup> Beck Anxiety Inventory,<sup>30</sup> 30-  
25 item Geriatric Depression Scale (GDS),<sup>31</sup> and the Hospital Anxiety and Depression  
26 Scale (HADS).<sup>32</sup> To harmonize scores, z-scores were created for each test using the  
27 mean and standard deviation at baseline. Individual test z-scores were then averaged  
28 to create overall z-scores for depression and anxiety.

## 1 **Statistical Analysis**

2 Statistical analyses were performed using *R* (version 4.1.2) and Stata (version 13.0).

## 3 **Outcomes**

4 The progression of variables of interest are described using annual mean and standardized  
5 response mean (SRM), which is computed by dividing the mean change from baseline of each  
6 individual patient by the standard deviation of the change of the total cohort (allowing diverse  
7 measures to be compared to one another). Linear mixed-effect modeling (LMEM)<sup>33</sup> was used to  
8 estimate the yearly progression rate of each variable of interest with subject (random slopes) and  
9 study center (random intercepts) as random effects and baseline age and follow-up year as fixed  
10 effects. Visual inspection of residual plots for each variable did not reveal obvious deviations  
11 from homoscedasticity or normality (**Supplementary Fig. 2**). Estimates of the annual  
12 progression rates were subdivided by phenoconversion status (PD-phenoconverters, DLB-  
13 phenoconverters, and those not known to have phenoconverted during 5 years of follow-up) and  
14 are displayed along with the overall estimated progression rate for the total cohort. MSA-  
15 phenoconverters were included as part of the total cohort analysis, but the progression of MSA-  
16 phenoconverters, specifically, could not be accurately calculated due to low numbers. Rates of  
17 progression between different sub-groups were compared using interaction terms between  
18 follow-up year and phenoconversion status; *p*-values were obtained by likelihood ratio tests of  
19 the full model with the interaction term against the model without the interaction term. Survival  
20 analysis for subjects that phenoconverted to a defined neurodegenerative disease was performed  
21 using Kaplan-Meier analysis to estimate annual phenoconversion risk.

22 Secondary analyses examining progression rates stratified by baseline age and by sex were  
23 performed. For age analysis, we excluded subjects over the age of 79 years at baseline since too  
24 few were studied to allow reliable estimates (**Supplementary Fig. 1**; also note that subjects of  
25 advanced age might be excluded from enrollment in a neuroprotective clinical trial).

## 26 **Missing data**

27 Imputation by linear interpolation<sup>34</sup> was used if data was missing in a single follow-up year  
28 between two other data points. Since data were not collected in years following a subject's  
29 phenoconversion, and since subsequent treatment could reduce the estimation of a marker's

1 progression, values were imputed in these years by adding the mean change of the whole group  
2 during that year to the last measured value (i.e., at phenoconversion).<sup>11</sup>

### 3 **Sample size calculations**

4 Sample size estimates for a hypothetical intervention to slow disease progression of each  
5 variable of interest were estimated by comparison of slopes between LMEMs for treated and  
6 untreated groups.<sup>35</sup> Sample size estimates were also calculated for time-to-event analyses<sup>36</sup> for a  
7 hypothetical trial in which phenoconversion is the primary outcome. Additional time-to-event  
8 analyses for significant motor decline (defined as a sustained increase in MDS-UPDRS-III of  $\geq 4$   
9 points),<sup>37</sup> a significant cognitive decline (defined as a sustained reduction in MoCA  $\geq 3$  points,  
10 i.e., an effect size  $\approx 1$  according to the baseline MoCA standard deviation), or a combined  
11 milestone of cognitive and/or motor decline. Similarly, a significant increase in the combined  
12 MDS-UPDRS-I+II+III score was defined as a sustained increase  $\geq 12$  points, based on the  
13 baseline standard deviation. A sustained change was defined as a change in score that was  
14 observed in two consecutive years. Sample sizes are presented for a 2-arm parallel trial in which  
15 treatment is expected to reduce the rate of progression by a constant amount throughout follow-  
16 up. Presented are required sample sizes to detect 30% or 50% treatment effects for a 2- or 3-year  
17 trial with periodic 6 month-follow-up (for continuous variable analysis) specifying 80% power  
18 and 2-sided  $\alpha=0.05$ .

### 19 **Data availability**

20 De-identified subject data used in this study are available upon reasonable request from the  
21 corresponding author (R.B.P.).

## 22 **Results**

### 23 **Subjects**

24 Detailed baseline demographics for each center are shown in **Supplementary Table 1** and  
25 summarized in **Table 1**. Data were collected from a total of 1647 subjects from 28 centers in 12  
26 countries, from which 210 were excluded for having only a single baseline visit, and 1 was  
27 excluded due to a diagnosis of PD at baseline. From the remaining 1436 subjects, 1160 (80.8%)  
28 met MDS prodromal PD criteria and were included in the primary analysis. Since only 10% of

1 subjects had follow-up data beyond five years, the majority of whom were followed by a single  
2 center (Montreal; **Fig. 1A**), analyses of variable progression and sample size calculations were  
3 limited to data from the first five years of follow-up. Mean age at baseline was  $68.5 \pm 7.0$  years,  
4 78.4% were male, time from iRBD diagnosis was  $1.28 \pm 2.3$  years, and time from self-reported  
5 iRBD symptom onset was  $6.4 \pm 6.4$  years. The mean follow-up time (i.e., the duration between  
6 baseline and last examination or time of phenoconversion) was  $3.3 \pm 2.2$  years, translating to  
7 3828 total person-years of follow-up.

8  
9 During five years of follow-up, 220 subjects were known to have phenoconverted to a defined  
10 neurodegenerative disease, including 129 (58.6%) who developed parkinsonism as the first  
11 disease manifestation (of whom 11 were eventually diagnosed with MSA) and 41.4% who  
12 developed dementia first. Using Kaplan-Meier analysis, this corresponded to a phenoconversion  
13 rate of 4.4% at 1 year, 18.2% at 3 years, and 31.7% at 5 years (**Fig. 1B**). Baseline characteristics  
14 of subjects who phenoconverted within 5 years are summarized in **Supplementary Tables 2-3**.  
15 DLB-phenoconverters were significantly older than both PD-phenoconverters and non-  
16 converters (DLB= $72.9 \pm 6.5$ , PD= $68.8 \pm 7.2$ , non-converters= $68.1 \pm 6.9$  years;  $p < 0.001$  for all  
17 comparisons).

18

## 19 **Progression of clinical markers**

20 The progression of clinical markers for the total cohort and subdivided by phenoconversion  
21 status over five years of follow-up are illustrated in **Fig. 2**, **Fig. 3** and **Supplementary Fig. 3**.  
22 Annual change as assessed by SRMs and estimated annual progression rate for each marker is  
23 detailed in **Table 2**, **Supplementary Table 4**, and **Fig. 4**, while estimated annual progression  
24 rate subdivided by phenoconversion status is detailed in **Table 3** and **Supplementary Table 5**.  
25 Progression rates for the entire cohort (without stratifying by MDS prodromal criteria) are shown  
26 in **Supplementary Tables 6-7**.

27

## 1 **Motor markers**

2 Motor symptoms and motor signs showed the greatest degree of progression over time (**Fig. 2**  
3 **and Table 2**). For example, MDS-UPDRS-III (excluding action tremor, which does not progress  
4 in iRBD)<sup>9</sup> had an estimated yearly progression rate of 1.73 points, with SRM=0.30 after 1 year  
5 and 0.97 after 5 years. Similarly, annual decline in Purdue Pegboard score was estimated to be -  
6 0.81 pegs, with SRM -0.35 and -1.15 at 1- and 5-year follow-up. More modest rates of  
7 progression were observed with MDS-UPDRS-II (SRM 0.2 and 0.8 at 1- and 5-year follow-up)  
8 and TUG velocity (SRM -0.09 and -0.67 at 1- and 5-year follow-up). A combined MDS-  
9 UPDRS-I+II+III score progressed by 2.81 points per year, with SRM=0.35 after 1 year and 1.20  
10 after 5 years.

11  
12 Phenoconverters had significantly greater annual progression rates in all motor variables  
13 compared with non-converters (**Table 3**), with the greatest distinction found in the MDS-  
14 UPDRS-III without action tremor score (annual progression in DLB=4.02, PD=3.69, non-  
15 converters=0.61 points;  $p<0.001$ ). When comparing between PD- and DLB-phenoconverters, a  
16 slight but statistically significant increased slope in PD-phenoconverters was observed in the  
17 MDS-UPDRS-II and MDS-UPDRS-III scores ( $p=0.037$  and  $p=0.008$ , respectively), although  
18 baseline MDS-UPDRS-III scores were significantly higher in DLB-phenoconverters  
19 (**Supplementary Table 3**,  $p=0.028$ ).

## 20 21 **Cognitive markers**

22 Within the total cohort, both MoCA and MMSE demonstrated slow progression in the average  
23 score over time (**Fig. 3 and Table 2**), with an estimated annual decline of -0.07 and -0.25 points,  
24 respectively. These were associated with 1- and 5-year SRMs of 0.03 to -0.22 and -0.07 to -0.58.

25  
26 A more dramatic decline was seen in phenoconverters compared with non-converters (**Table 3**),  
27 with annual decline in MMSE score of -0.09 points in non-converters vs. -0.42 in PD-  
28 phenoconverters and -0.81 DLB-phenoconverters ( $p<0.001$ ). Estimated annual progression in

1 MoCA score in fact slightly increased in non-converters compared with a decline in  
2 phenoconverters (DLB=-0.73, PD=-0.09, non-converters=0.06 points;  $p<0.001$ ). Rates of  
3 progression in both MMSE and MoCA were significantly different when comparing between  
4 PD- and DLB-phenoconverters ( $p<0.001$  for both), with greater decline in DLB-  
5 phenoconverters.

## 7 **Autonomic symptoms and signs**

8 Autonomic symptoms as assessed by SCOPA-AUT total score increased slightly over time (**Fig.**  
9 **3, Supplemental Fig. 3, Table 2, and Supplementary Table 4**), with estimated annual  
10 progression rate of 0.36 and 1- and 5-year SRMs of 0.13 and 0.31, respectively. Autonomic signs  
11 as assessed by orthostatic blood pressure showed mild increase in systolic pressure drop over  
12 time, with an estimated annual progression rate of 1.44 mmHg (1- and 5-year SRMs of 0.08 to  
13 0.36).

14  
15 Although PD-phenoconverters had a similarly modest annual rate of progression in total  
16 SCOPA-AUT score compared with non-converters, DLB-phenoconverters had a significantly  
17 increased rate (DLB =1.57, PD=0.15, non-converters=0.20;  $p<0.001$ ). This was driven by  
18 increased annual rates of progression in SCOPA-urinary and SCOPA-cardiovascular sub-scores  
19 (**Supplementary Fig. 3 and Supplementary Table 5**), which also individually differed  
20 significantly from PD- phenoconverters ( $p=0.004$  and  $p<0.001$ , respectively). When comparing  
21 the progression of postural systolic drop, although phenoconverters had a significantly increased  
22 rate of progression relative to non-phenoconverters ( $p=0.002$ ), no significant difference was  
23 observed between PD- and DLB-phenoconverters ( $p=0.553$ ).

## 25 **Olfactory function**

26 Olfactory z-scores slightly decreased over time in the total cohort (**Fig. 3 and Table 2**), with an  
27 estimated yearly progression rate of -0.09 and SRMs at 1- and 5-year follow-up of -0.07 and -  
28 0.64, respectively. The estimated yearly progression rate was significantly greater in PD- and

1 DLB-phenoconverters (-0.28 in both) compared with non-converters (-0.06,  $p < 0.001$ ), without  
2 any significant difference between PD and DLB-phenoconverters ( $p = 0.958$ ).

3

#### 4 **Sleep symptoms**

5 Sleep quality, as assessed by ESS, ISI, RBDSQ, and PSQI, paradoxically showed slight  
6 improvement in scores over time (**Fig. 3 and Table 2**), with SRMs ranging from -0.05 to -0.27 at  
7 1-year follow-up and -0.17 to -0.52 at 5-year follow-up. When comparing non-converters and  
8 phenoconverters, a significant difference was seen only in ISI score (DLB=-0.99, PD=-0.77,  
9 non-converters=-0.43;  $p = 0.006$ ).

10

#### 11 **Psychiatric symptoms**

12 Both depression and anxiety z-scores progressed only minimally or not at all, with SRMs  
13 ranging from -0.02 to 0.20 during the five years of follow-up (**Fig. 3 and Table 2**). No  
14 significant difference in the annual progression rate between phenoconverters and non-  
15 phenoconverters was observed.

16

#### 17 **Progression rates stratified by baseline age and by sex**

18 Age at baseline followed a roughly normal distribution, with a median age of  $68.8 \pm 7.0$  years  
19 (**Supplementary Fig. 1**). The results of clinical marker progression stratified by decade are  
20 shown in **Supplementary Fig. 5** and **Supplementary Table 8**. In general, clinical markers  
21 progressed along similar trajectories, with faster rates of decline in motor and cognitive scores  
22 among older participants (e.g. MDS-UPDRS-III progression at ages 50-59=1.08, ages 60-  
23 69=1.45, ages 70-79=1.78 points). With respect to sex, clinical markers progressed at similar  
24 rates between sexes, except for olfactory loss, which did not progress in females, and RBDSQ  
25 and PSQI, which worsened in females (**Supplementary Fig. 6** and **Supplementary Table 9**).

26

## 1 **Sample size calculations**

2 Using the estimated yearly progression rate of each variable, we calculated the required sample  
3 sizes for an interventional 1:1 placebo-controlled trial at different treatment efficacies (30% or  
4 50% reduction in clinical progression) for different study lengths (**Table 4** and **Supplementary**  
5 **Fig. 4**). For example, assuming a treatment efficacy of 50% reduction in the progression of  
6 MDS-UPDRS-III (excluding action tremor) with 6-month follow-up periods, the required sample  
7 size at 80% power would be 213 subjects per group for a 2-year study. Using a combined MDS-  
8 UPDRS score (i.e. the sum of parts I, II, and III) would require slightly fewer subjects at 183 per  
9 group for a 2-year study. Under similar assumptions, based on time-to-event analysis to reduce  
10 the rate of phenoconversion by 50%, we estimated that 409 subjects per arm would need to be  
11 enrolled in a 2-year trial. The most efficient trial design was found to be a combined motor and  
12 cognitive endpoint of a sustained increase in MDS-UPDRS-III (excluding action tremor) score  $\geq$   
13 4 and/or a sustained decrease in MoCA score  $\geq$  3; this provided an estimated sample size of 117  
14 subjects per arm in a 2-year study and 88 subjects in a 3-year study (with 389 and 294 subjects  
15 for an agent with 30% efficacy).

16  
17 Sample sizes were also calculated for the entire cohort, including subjects that did not meet MDS  
18 prodromal PD criteria (**Supplementary Table 10**). This increased sample size requirements for  
19 the majority of continuous motor variables or event milestones by approximately 10-30%.

20  
21 Aside from increasing the assumed treatment effect and stratifying by MDS prodromal PD  
22 criteria, the other driver of required sample sizes was the extent of follow-up duration  
23 (**Supplementary Fig. 4**). Increasing the follow-up time from 1 to 2 years resulted in greater  
24 sample size reductions in all variables tested than any increases beyond 2 years. For example, a  
25 1-year trial targeting a 50% reduction of the combined motor and cognitive endpoint required  
26 229 subjects, versus 117 subjects in a 2-year trial, or 88 subjects for a 3-year trial.

27



## 1 **Discussion**

2 This international longitudinal prospective study represents the largest and most comprehensive  
3 systematic assessment of clinical marker progression in iRBD that has been performed. We  
4 demonstrate several important insights, including: (i) motor assessment using the MDS-UPDRS-  
5 III and quantitative motor testing shows the greatest degree of progression over time; (ii) there is  
6 moderate progression of other non-motor markers, particularly the MDS-UPDRS-II, MMSE, and  
7 olfactory scores, and limited to no progression in psychiatric and some autonomic measures; (iii)  
8 while phenoconverters showed overall greater progression than non-converters in motor,  
9 olfactory, cognitive, and certain autonomic markers, the only robust difference in progression  
10 between PD and DLB-phenoconverters was in cognitive testing; and (iv) the most efficient trial  
11 design for future randomized trials was a combined endpoint of a sustained increase in MDS-  
12 UPDRS-III and/or a sustained decrease in MoCA score, while stratifying by MDS prodromal PD  
13 criteria and extending trial duration from 1 to 2 years yielded the largest reductions in sample  
14 size.

### 16 **Clinical marker progression**

17 Quantitative motor assessment by standardized clinical exam or simple office-based motor  
18 testing showed clear progression over the study period, in keeping with prior studies.<sup>7,9,11</sup>  
19 Unsurprisingly, given that motor function is the primary means of defining parkinsonism,  
20 phenoconverters had significantly increased rates of progression compared with non-converters.

21 With respect to non-motor markers, although cognitive function showed moderate decline  
22 overall, scores remained stable in non-converters but dramatically declined among  
23 phenoconverters. This bimodal distribution likely explains the large difference in sample size  
24 requirements when using MoCA as a continuous variable (which includes the stable scores of  
25 non-converters, and which could be confounded by practice effects in cognitively-spared  
26 subjects) rather than as a milestone of sustained decrease (which dichotomizes into  
27 phenoconverters and non-converters).

28

1 Olfactory and autonomic dysfunction only mildly progressed when assessed in the total cohort,  
2 as previously observed,<sup>9,38</sup> and is in keeping with being among the earliest markers of prodromal  
3 disease. Indeed, the inclusion of subjects not meeting MDS prodromal PD criteria (i.e. those  
4 likeliest to have more olfactory and autonomic “reserve” to lose) paradoxically decreased the  
5 sample size requirements for these variables. Although olfactory dysfunction in phenoconverters  
6 appeared to decline more rapidly, this could reflect progressive cognitive dysfunction (i.e.  
7 olfactory memory) rather than continued olfactory loss alone.<sup>39</sup> Increasing postural systolic drop  
8 was also observed in phenoconverters, which is recognized to be predictive of eventual  
9 phenoconversion.<sup>40</sup>

10  
11 Psychiatric symptoms and sleep symptoms were generally stable over time, in keeping with prior  
12 studies.<sup>11,41</sup> In phenoconverters, insomnia scores in fact significantly improved over time relative  
13 to non-converters, which could reflect a general subthreshold increase in sleep drive without  
14 overt daytime somnolence as patients approach a defined neurodegenerative disease.  
15 Alternatively, these trends could be resultant from treatment for sleep or psychiatric disorders.

16  
17 Secondary analyses stratifying clinical marker progression by baseline age demonstrated  
18 somewhat faster rates of decline in motor and cognitive measures in older subjects. By contrast,  
19 there were minimal differences when stratifying by sex.

## 21 **Phenoconversion rate**

22 We found that phenoconversion rates were slightly lower than expected compared to two recent  
23 large IRBDSG studies, despite similar baseline ages.<sup>7,10</sup> Our 3-year phenoconversion risk was  
24 found to be 18.2% vs. 17.9% and 24.2% in the other studies, despite the fact that this study  
25 selected subjects that met prodromal PD criteria. Several explanations likely account of this.  
26 First, a lower phenoconversion rate was observed in a single large center (Berlin) which had no  
27 phenoconversions at all over a 2.7-year follow-up; removal of this center increased the 3-year  
28 risk to 20.1%. Second, although there is some overlap in the patient populations with the prior  
29 studies, this study includes 8 new centers contributing 155 subjects (13.4% of included subjects),

1 while several large centers with higher phenoconversion rates that were included in the prior  
2 studies were unable to contribute to this one. However, newer centers did not have lower rates of  
3 phenoconversion (3-year risk: 19.8%). Third, the inclusion criteria may have enriched toward an  
4 overall healthier population than the previous studies. By design, subjects were required to attend  
5 periodic and structured assessments longitudinally (whereas only a follow-up clinical  
6 examination was required in the other studies), which may have discouraged subjects with  
7 mobility or cognitive issues (i.e. those most likely to phenoconvert) from being enrolled.<sup>9</sup> This  
8 would be consistent with the unusually low phenoconversion rate in the first year (4.4%) vs. an  
9 average annual conversion rate of 6.1% in years 2-5 (a rate consistent with prior studies). In any  
10 event, although this study population had lower rates of phenoconversion than expected,  
11 longitudinal patient retention is a critical aspect of any proposed therapeutic trial. Therefore, the  
12 subjects included in this study are probably representative of those likeliest to be enrolled in a  
13 future trial.

14

## 15 **Prodromal Parkinson's disease versus prodromal dementia with** 16 **Lewy bodies**

17 When classified according to the initial phenoconversion event (parkinsonism-first vs. dementia-  
18 first), PD- and DLB-phenoconverters showed remarkably similar age-adjusted rates of  
19 progression. For example, among motor signs, only MDS-UPDRS-III showed a slightly  
20 increased rate in PD-phenoconverters, with the difference possibly explained by the higher  
21 baseline MDS-UPDRS-III score in DLB-phenoconverters. This is concordant with a recent  
22 single-center study in which no significant between-group difference in motor trajectories was  
23 observed.<sup>9</sup> An increased rate of progression in SCOPA-AUT was also observed in DLB-  
24 phenoconverters. This was primarily driven by an increased cardiovascular subscore, which  
25 largely reflects orthostatic hypotension symptoms; nevertheless, no difference in orthostatic  
26 blood pressure was seen between PD- and DLB-phenoconverters, in agreement with studies with  
27 more precise orthostatic testing.<sup>42</sup>

28

1 Overall, the only robust differentiating clinical marker between PD- and DLB-first  
2 phenoconverters was the higher rate of cognitive decline in DLB, as would be expected by  
3 definition. This is in agreement with two recent IRBDSG studies (with approximately half of  
4 subjects overlapping between them), which observed that baseline cognitive function was the  
5 only clear differentiating clinical predictor between PD and DLB phenoconversion.<sup>7,13</sup> Thus,  
6 while clear differences in the progression of clinical variables are apparent between those at  
7 higher and lower risk of phenoconversion (i.e. phenoconverters and non-converters in this  
8 study), the subtypes of prodromal synucleinopathies appear to follow very similar clinical  
9 courses. The underlying pathological substrate that accounts for this remains unclear. This could  
10 reflect either alternate pathways of synuclein spread or coexistent amyloid or tau pathology  
11 driving earlier cortical neurodegeneration.<sup>43,44</sup> It is important to note that all subjects in this study  
12 were iRBD patients, who generally have a more diffuse burden of synucleinopathy, and  
13 consequently more non-motor manifestations.<sup>6</sup> iRBD identifies subtypes of PD and DLB that are  
14 associated with greater progression of motor and non-motor symptoms, diffuse and severe  
15 deposition of synuclein at autopsy, enhanced patterns of atrophy earlier in the disease course, and  
16 overall poorer prognosis.<sup>45,46</sup> This PD subtype is therefore characterized by a different speed and  
17 anatomical pattern of progression than PD subjects without RBD. Therefore, it is not clear to  
18 what degree the findings in this study are translatable to prodromal subtypes that do not have  
19 iRBD.

## 21 **Sample size**

22 We calculated sample size estimates for neuroprotective trials using both the progression of  
23 continuous clinical variables and categorical events (phenoconversion and motor and cognitive  
24 decline milestones) as endpoints. Importantly, we first stratified by MDS prodromal criteria,  
25 which retained >80% of subjects; this reduces sample sizes by approximately 10-30% for most  
26 motor clinical markers or events of interest. For continuous motor variables, sample sizes for a 2-  
27 year trial with HR=0.5 ranged from 151-560 subjects per arm, while substantially higher  
28 numbers were required for non-motor variables. Under similar assumptions, sample size  
29 estimates using the sum of MDS-UPDRS-I, -II, and -III sub-scores resulted in 183 subjects per  
30 arm. The most efficient trial design was a combined motor and cognitive endpoint of a sustained

1 increase in MDS-UPDRS-III and/or a sustained decrease in MoCA score, which required only  
2 117 subjects for a 2-year study at HR=0.5. These sample size estimates are broadly similar to  
3 those calculated in a recent single-center study of clinical markers.<sup>11</sup> They are also similar to the  
4 sample sizes calculated in a recent single-center study that assessed serial DAT-PET imaging  
5 (i.e. sample size=94 for standard DAT-PET analysis).<sup>47</sup> Notably, using the milestone of  
6 phenoconversion to overt disease required substantially larger numbers. Finally, aside from  
7 increasing the assumed treatment effect and stratifying by MDS prodromal criteria, sample sizes  
8 could also be substantially reduced by increasing the follow-up time from 1 to 2 years, whereas  
9 lesser reductions were observed if trials were extended to 3 years or beyond.

## 11 **Strengths and limitations**

12 Strengths of this study include a large study population prospectively followed over a period of 5  
13 years. Clinical variables representative of most of the critical predictors of phenoconversion were  
14 systematically measured, including the motor, cognitive, olfactory, autonomic, psychiatric, and  
15 sleep domains. However, several limitations should be discussed. Since each of the 28 centers  
16 used their own study protocol, which varied in predictors assessed, methods of assessment, and  
17 follow-up frequency, a pragmatic approach was taken with respect to data collection, in which  
18 different clinical tests were harmonized across centers in order to maximize recruitment and  
19 simplify the analysis. Although different methods of measuring a clinical marker undoubtedly  
20 vary in sensitivity and statistical power, they have all been shown to have similar performance in  
21 PD.<sup>15,18,48,49</sup> Moreover, in this study, all scores were adjusted by center in the LMEMs and  
22 followed a broadly similar trend when SRMs were evaluated individually (data not shown).  
23 Second, some clinical markers that have been shown to have excellent predictive value were not  
24 included in the analysis since they were only performed in sufficient numbers by a single center  
25 (e.g. alternate tap test, color-vision testing, etc.).<sup>9,11</sup> The IRBDSG is currently planning a  
26 recommended minimal core data collection protocol that will be essential for standardization  
27 between centers in the future. Additionally, longitudinal assessment of imaging<sup>13,50</sup> and fluid<sup>51</sup>  
28 biomarkers to evaluate neuropathological changes as complementary measures of progression  
29 are needed. Third is the use of a generally conservative method of imputation to estimate  
30 progression in subjects after phenoconversion, particularly since certain markers can increase

1 exponentially closer to the time of phenoconversion.<sup>9</sup> Notably, a similar issue would exist in any  
2 real-life therapeutic trial, since it would be unethical to withhold symptomatic treatment in  
3 phenoconverted subjects. Fourth, medication use could impact upon the progression of markers.  
4 Although medication use was not longitudinally collected, the use of either melatonin,  
5 clonazepam, or antidepressants at baseline showed only a statistically significant effect of  
6 clonazepam on annual decline in MoCA score (clonazepam use=-0.19 points vs non-use=0.012  
7 points,  $p=0.026$ ; and data not shown). Fifth, subjects destined to convert to a parkinsonism-first  
8 vs. dementia-first phenotype cannot be reliably distinguished at time of iRBD diagnosis. If the  
9 underlying pathomechanisms that drive neurodegeneration are substantially different between  
10 the two,<sup>43,44</sup> a neuroprotective therapy targeting a single pathomechanism may inadequately slow  
11 progression in a substantial subgroup of the population, although this could be mitigated by  
12 baseline neurocognitive testing.<sup>52,53</sup> Similarly, the 5-10% of subjects expected to phenoconvert to  
13 MSA are likely to progress very differently, although this could be mitigated by screening  
14 subjects for olfactory loss.<sup>7</sup> Finally, an assumption of LMEMs is linearity over time. Previous  
15 studies have demonstrated heterogeneity in the pattern of emergence among prodromal features:  
16 some features emerge early and subsequently remain fairly stable over time (e.g., constipation),  
17 whereas other features emerge late and increase quickly in the last few years before clinical  
18 diagnosis (e.g. motor signs).<sup>9</sup> Consequently, the current results may overestimate the rate of  
19 progression of early prodromal features during the last years of the prodromal phase, and  
20 conversely underestimate the rate of progression of late-emerging prodromal features. In keeping  
21 with this, those phenoconverting within 3-5 years had faster rates of progression in motor and  
22 cognitive measures and generally less progression in markers known to have longer latencies.  
23 Assuming that a future neuroprotective trial would not run longer than 3 years, using a 5-year  
24 window for the LMEMs was felt to be a compromise between the robust inclusion of datapoints  
25 for model precision versus achieving an accuracy that reflects the reality of recruiting a patient in  
26 whom the time until phenoconversion to overt disease will be unknown.

27

## 28 **Conclusion**

29 To conclude, we confirmed patterns of clinical marker progression in prodromal synucleinopathy  
30 and demonstrated predicted sample sizes to inform future neuroprotective trials.

## 1 **Funding**

2 SJ was supported by an Edmond J. Safra Fellowship in Movement Disorders from the Michael J.  
3 Fox Foundation.

4 The Oxford Discovery cohort (lead M.T.Hu) is supported by Parkinson's UK and the National  
5 Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), UK.

6 KY Jung received research fund supported by the National Research Foundation of Korea (NRF)  
7 grant funded by the Korean government (MSIP) (2017M3C7A1029688, 2017R1A2B2012280)  
8 and NRF-2022R1H1A2092329.

9 WO is a Hertie-Senior Research Professor supported by the Charitable Hertie Foundation,  
10 Frankfurt/Main, Germany. AJ and WO are supported by the ParkinsonFonds Deutschland.

11 JFG was funded by a grant from the CIHR and he holds a Canada Research Chair in Cognitive  
12 Decline in Pathological Aging.

13 RBP was funded by a grant from the Canadian Institutes of Health Research (CIHR).

14

## 15 **Competing interests**

16 The authors report no competing interests.

17

## 18 **Supplementary material**

19 Supplementary material is available at *Brain* online.

## 1 **References**

- 2 1. Lang AE, Siderowf AD, Macklin EA, et al. Trial of Cinpanemab in Early Parkinson's Disease.  
3 <https://doi.org/10.1056/NEJMoa2203395>. 2022;387(5):408-420. doi:10.1056/NEJMoa2203395
- 4 2. Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of Prasinezumab in Early-Stage Parkinson's  
5 Disease. *N Engl J Med*. 2022;387(5):421-432.  
6 doi:10.1056/NEJMoa2202867/SUPPL\_FILE/NEJMoa2202867\_DATA-SHARING.PDF
- 7 3. Lang FM, Kwon DY, Aarsland D, et al. An international, randomized, placebo-controlled, phase  
8 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). Published online  
9 2021. doi:10.1002/trc2.12171
- 10 4. Postuma RB. Neuroprotective Trials in REM Sleep Behavior Disorder The Way Forward Becomes  
11 Clearer. Published online 2022. doi:10.1212/WNL.000000000000200235
- 12 5. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's  
13 disease. *Movement Disorders*. 2019;34(10):1464-1470. doi:10.1002/MDS.27802
- 14 6. Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes — key  
15 to understanding heterogeneity. *Nat Rev Neurol*. 2021;17(6):349-361. doi:10.1038/s41582-021-  
16 00486-9
- 17 7. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in  
18 idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. 2019;142(3):744-759.  
19 doi:10.1093/BRAIN/AWZ030
- 20 8. Postuma RB, Iranzo A, Hög B, et al. Risk factors for neurodegeneration in idiopathic rapid eye  
21 movement sleep behavior disorder: A multicenter study. *Ann Neurol*. 2015;77(5):830-839.  
22 doi:10.1002/ANA.24385
- 23 9. Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of  
24 prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. *Brain*.  
25 2019;142(7):2051-2067. doi:10.1093/BRAIN/AWZ111
- 26 10. Zhang H, Iranzo A, Högl B, et al. Risk Factors for Phenoconversion in Rapid Eye Movement Sleep  
27 Behavior Disorder. *Ann Neurol*. 2022;91(3):404-416. doi:10.1002/ANA.26298



- 1 11. Alotaibi F, Pelletier A, Gagnon JF, Montplaisir JY, Postuma RB. Prodromal Marker Progression in  
2 Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Sample Size for Clinical Trials.  
3 *Movement Disorders*. 2019;34(12):1914-1919. doi:10.1002/MDS.27869
- 4 12. Kogan R v., Janzen A, Meles SK, et al. Four-Year Follow-up of [18F]Fluorodeoxyglucose Positron  
5 Emission Tomography–Based Parkinson’s Disease–Related Pattern Expression in 20 Patients  
6 with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression.  
7 *Movement Disorders*. 2021;36(1):230-235. doi:10.1002/MDS.28260
- 8 13. Arnaldi D, Chincarini A, Hu MT, et al. Dopaminergic imaging and clinical predictors for  
9 phenoconversion of REM sleep behaviour disorder. *Brain*. 2021;144(1):278-287.  
10 doi:10.1093/BRAIN/AWAA365
- 11 14. Sateia MJ. International Classification of Sleep Disorders-Third Edition. *Chest*. 2014;146(5):1387-  
12 1394. doi:10.1378/CHEST.14-0970
- 13 15. Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson’s disease rating scale scores to  
14 Movement Disorder Society-unified Parkinson’s disease rating scale scores. *Movement*  
15 *Disorders*. 2012;27(10):1239-1242. doi:10.1002/MDS.25122
- 16 16. Podsiadlo D, Richardson S. The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail  
17 Elderly Persons. *J Am Geriatr Soc*. 1991;39(2):142-148. doi:10.1111/J.1532-  
18 5415.1991.TB01616.X
- 19 17. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson  
20 disease in idiopathic REM sleep behavior disorder. *Neurology*. 2006;66(6):845-851.  
21 doi:10.1212/01.WNL.0000203648.80727.5B
- 22 18. Lawton M, Hu MTM, Baig F, et al. Equating scores of the University of Pennsylvania Smell  
23 Identification Test and Sniffin’ Sticks test in patients with Parkinson’s disease. *Parkinsonism*  
24 *Relat Disord*. 2016;33:96-101. doi:10.1016/j.parkreldis.2016.09.023
- 25 19. Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin’ Sticks normative  
26 data based on an extended sample of 9139 subjects. *European Archives of Oto-Rhino-*  
27 *Laryngology*. 2019;276(3):719-728. doi:10.1007/S00405-018-5248-1/TABLES/2
- 28 20. Hummel T, Konnerth CG, Rosenheim K, Kobal G. Screening of olfactory function with a four-  
29 minute odor identification test: Reliability, normative data, and investigations in patients with

- 1 olfactory loss. *Annals of Otolaryngology, Rhinology and Laryngology*. 2001;110(10):976-981.  
2 doi:10.1177/000348940111001015
- 3 21. Menon C, Westervelt HJ, Jahn DR, Dressel JA, O'Bryant SE. Normative Performance on the Brief  
4 Smell Identification Test (BSIT) in a Multi-Ethnic Bilingual Cohort: A Project FRONTIER Study 1.  
5 <http://dx.doi.org/101080/138540462013796406>. 2013;27(6):946-961.  
6 doi:10.1080/13854046.2013.796406
- 7 22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.  
8 *Sleep*. 1991;14(6):540-545. doi:10.1093/SLEEP/14.6.540
- 9 23. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome  
10 measure for insomnia research. *Sleep Med*. 2001;2(4):297-307. doi:10.1016/S1389-  
11 9457(00)00065-4
- 12 24. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a  
13 new instrument for psychiatric practice and research. *Psychiatry Res*. 1989;28(2):193-213.  
14 doi:10.1016/0165-1781(89)90047-4
- 15 25. Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The  
16 REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. *Mov*  
17 *Disord*. 2007;22(16):2386-2393. doi:10.1002/MDS.21740
- 18 26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the  
19 cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198.  
20 doi:10.1016/0022-3956(75)90026-6
- 21 27. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A  
22 Brief Screening Tool For Mild Cognitive Impairment. *J Am Geriatr Soc*. 2005;53(4):695-699.  
23 doi:10.1111/J.1532-5415.2005.53221.X
- 24 28. Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in  
25 Parkinson's disease: the SCOPA-AUT. *Mov Disord*. 2004;19(11):1306-1312.  
26 doi:10.1002/MDS.20153
- 27 29. Beck A, Steer R, Brown G. Beck depression inventory--II. *psycnet.apa.org*. Published online  
28 1996. Accessed August 15, 2022. <https://psycnet.apa.org/doiLanding?doi=10.1037/t00742-000>

- 1 30. Beck AT, Epstein N, Brown G, Steer RA. An Inventory for Measuring Clinical Anxiety:  
2 Psychometric Properties. *J Consult Clin Psychol*. 1988;56(6):893-897. doi:10.1037/0022-  
3 006X.56.6.893
- 4 31. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression  
5 screening scale: a preliminary report. *J Psychiatr Res*. 1982;17(1):37-49. doi:10.1016/0022-  
6 3956(82)90033-4
- 7 32. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*.  
8 1983;67(6):361-370. doi:10.1111/J.1600-0447.1983.TB09716.X
- 9 33. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: Tests in Linear Mixed Effects  
10 Models. *J Stat Softw*. 2017;82(13):1-26. doi:10.18637/JSS.V082.I13
- 11 34. Moritz S, Bartz-Beielstein T. Time Series Missing Value Imputation [R package imputeTS version  
12 3.2]. *R Journal*. 2021;9(1):207-218. doi:10.32614/RJ-2017-009
- 13 35. Nash S, Morgan KE, Frost C, Mulick A. Power and sample-size calculations for trials that  
14 compare slopes over time: Introducing the slopepower command:  
15 <https://doi.org/10.1177/1536867X211045512>. 2021;21(3):575-601.  
16 doi:10.1177/1536867X211045512
- 17 36. Anderson K. gsDesign. Published 2022. Accessed August 15, 2022. [https://cran.r-](https://cran.r-project.org/web/packages/gDesign/index.html)  
18 [project.org/web/packages/gDesign/index.html](https://cran.r-project.org/web/packages/gDesign/index.html)
- 19 37. Horváth K, Aschermann Z, Ács P, et al. Minimal clinically important difference on the Motor  
20 Examination part of MDS-UPDRS. *Parkinsonism Relat Disord*. 2015;21(12):1421-1426.  
21 doi:10.1016/J.PARKRELDIS.2015.10.006
- 22 38. Iranzo A, Serradell M, Vilaseca I, et al. Longitudinal assessment of olfactory function in  
23 idiopathic REM sleep behavior disorder. *Parkinsonism Relat Disord*. 2013;19(6):600-604.  
24 doi:10.1016/J.PARKRELDIS.2013.02.009
- 25 39. Shin C, Lee JY, Kim YK, et al. Cognitive decline in association with hyposmia in idiopathic rapid  
26 eye movement sleep behavior disorder: a prospective 2-year follow-up study. *Eur J Neurol*.  
27 2019;26(11):1417-1420. doi:10.1111/ENE.14025
- 28 40. Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension A 10-year  
29 follow-up study. Published online 2015.

- 1 41. Postuma RB, Gagnon JF, Pelletier A, Montplaisir JY. Insomnia and somnolence in idiopathic  
2 RBD: a prospective cohort study. *NPJ Parkinsons Dis.* 2017;3(1). doi:10.1038/S41531-017-0011-  
3 7
- 4 42. McCarter SJ, Gehrking TL, st. Louis EK, et al. Autonomic dysfunction and phenoconversion in  
5 idiopathic REM sleep behavior disorder. *Clinical Autonomic Research.* 2020;30(3):207-213.  
6 doi:10.1007/S10286-020-00674-5/TABLES/3
- 7 43. Foffani G, Obeso JA. A Cortical Pathogenic Theory of Parkinson's Disease. *Neuron.*  
8 2018;99(6):1116-1128. doi:10.1016/J.NEURON.2018.07.028
- 9 44. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson's  
10 disease. *Movement Disorders.* 2016;31(8):1114-1119. doi:10.1002/MDS.26605
- 11 45. Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping  
12 Parkinson's disease: biomarkers and longitudinal progression. *Brain.* 2017;140(7):1959-1976.  
13 doi:10.1093/BRAIN/AWX118
- 14 46. Postuma RB, Adler CH, Dugger BN, et al. REM sleep behavior disorder and neuropathology in  
15 Parkinson's disease. *Movement Disorders.* 2015;30(10):1413-1417. doi:10.1002/MDS.26347
- 16 47. Shin JH, Lee JY, Kim YK, et al. Longitudinal change in dopamine transporter availability in  
17 idiopathic REM sleep behavior disorder. *Neurology.* 2020;95(23):e3081-e3092.  
18 doi:10.1212/WNL.00000000000010942
- 19 48. Williams JR, Hirsch ES, Anderson K, et al. A comparison of nine scales to detect depression in  
20 Parkinson disease: Which scale to use? *Neurology.* 2012;78(13):998.  
21 doi:10.1212/WNL.0B013E31824D587F
- 22 49. Leentjens AFG, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P. Anxiety rating  
23 scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck  
24 anxiety inventory, and the hospital anxiety and depression scale. *Mov Disord.* 2011;26(3):407-  
25 415. doi:10.1002/MDS.23184
- 26 50. Rahayel S, Postuma RB, Montplaisir J, et al. A Prodromal Brain-Clinical Pattern of Cognition in  
27 Synucleinopathies. *Ann Neurol.* 2021;89(2):341-357. doi:10.1002/ANA.25962

- 1 51. Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of  $\alpha$ -synuclein in CSF by RT-QulC in  
2 patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal  
3 observational study. *Lancet Neurol.* 2021;20(3):203-212. doi:10.1016/S1474-4422(20)30449-X
- 4 52. Marchand DG, Montplaisir J, Postuma RB, Rahayel S, Gagnon JF. Detecting the Cognitive  
5 Prodrome of Dementia with Lewy Bodies: A Prospective Study of REM Sleep Behavior Disorder.  
6 *Sleep.* 2017;40(1). doi:10.1093/SLEEP/ZSW014
- 7 53. Marchand DG, Postuma RB, Escudier F, et al. How does dementia with Lewy bodies  
8 start? prodromal cognitive changes in REM sleep behavior disorder. *Ann Neurol.*  
9 2018;83(5):1016-1026. doi:10.1002/ANA.25239
- 10

## 11 **Figure legends**

12 **Figure 1 Study profile.** (A) Subjects enrolled in the study grouped by country of origin over  
13 time. More subjects were seen at 2-year follow-up than 1-year follow-up since some centers  
14 tended to have longer follow-up times (e.g., 18 months to 2 years). (B) Kaplan-Meier survival  
15 plot of disease-free survival (i.e. free of phenoconversion) with 95% confidence intervals shaded.

16

17 **Figure 2 Motor outcome measures over 5 years of follow-up for the total cohort and by**  
18 **phenoconversion status.** Individual dots represent each subject; solid lines represent estimated  
19 progression by linear mixed-effect modeling.

20

21 **Figure 3 Non-motor outcome measures over 5 years of follow-up for the total cohort and by**  
22 **phenoconversion status.** Individual dots represent each subject; solid lines represent estimated  
23 progression by linear mixed-effect modeling.

24

25 **Figure 4 Normalized motor and non-motor outcome measures over 5 years of follow-up.**  
26 Results were normalized for comparison between variables by standardized response means  
27 (SRM), which is computed by dividing the mean change from baseline of each individual patient  
28 by the standard deviation of the change of the total cohort.

1 **Table I Baseline demographics and phenoconversion outcomes from baseline to 5-year follow-up**

	<b>Baseline (n=1160)</b>	<b>1-year follow-up (n=767)</b>	<b>2-year follow-up (n=783)</b>	<b>3-year follow-up (n=477)</b>	<b>4-year follow-up (n=311)</b>	<b>5-year follow-up (n=228)</b>
<b>Demographics</b>						
Age, years	68.5 ± 7.0	69.5 ± 7.1	70.3 ± 6.8	70.8 ± 6.7	72.3 ± 6.5	73.0 ± 6.4
Sex, % male	78.4	78.5	80.5	82.2	80.7	83.3
Handedness, % right	90.6	92.8	90.4	90.9	90.4	87.4
<b>RBD course</b>						
Years from diagnosis	1.28 ± 2.3	2.2 ± 2.3	3.1 ± 2.2	4.4 ± 2.4	5.1 ± 2.0	6.4 ± 2.2
Years from symptom onset	6.4 ± 6.4	7.84 ± 8.0	8.8 ± 7.9	10.0 ± 8.7	11.0 ± 9.4	12.5 ± 10.4
Years from baseline visit	-	1.1 ± 0.4	1.98 ± 0.4	3.0 ± 0.4	4.0 ± 0.4	5.1 ± 0.5
<b>Phenoconversion outcomes</b>						
Phenoconverted, %	-	4.4	11.5	18.2	25.3	31.7
Phenoconverted, n	-	51	69	45	33	23
PD	-	29	35	23	20	11
DLB	-	18	31	18	11	12
MSA	-	4	3	3	2	0

2 Data are presented as mean ± SD. Yearly phenoconverted percentages were calculated by Kaplan-Meier survival analysis. More subjects were  
3 seen at 2-year follow-up than 1-year follow-up since some centers tended to have longer follow-up times (18 months to 2 years).  
4 DLB=dementia with Lewy bodies; MSA=multiple system atrophy; PD=Parkinson's disease.

5  
6

1 **Table 2 Annual marker outcomes and estimated progression rates**

Marker	Baseline		1-year follow-up		2-year follow-up		3-year follow-up		5-year follow-up		Yearly progression
	Centers, n	Mean $\pm$ SD (n)	Mean $\pm$ SD (n)	SR M	Mean $\pm$ SD (n)	SR M	Mean $\pm$ SD (n)	SR M	Mean $\pm$ SD (n)	SR M	Estimate [95 % CI]
<b>MDS-UPDRS</b>											
MDS-UPDRS-I	15	7.67 $\pm$ 6.01 (482)	8.14 $\pm$ 5.80 (431)	0.13	8.45 $\pm$ 5.90 (359)	0.14	8.62 $\pm$ 5.55 (240)	0.20	10.48 $\pm$ 5.98 (185)	0.54	0.48 [0.34, 0.61]
MDS-UPDRS-II	18	2.31 $\pm$ 3.48 (740)	2.81 $\pm$ 3.88 (665)	0.20	3.3 $\pm$ 4.37 (537)	0.26	4.31 $\pm$ 5.1 (378)	0.44	7.02 $\pm$ 6.71 (294)	0.80	0.65 [0.55, 0.75]
MDS-UPDRS-III	27	4.02 $\pm$ 5.03 (1095)	5.3 $\pm$ 7.04 (989)	0.26	6.9 $\pm$ 8.98 (751)	0.33	10.0 $\pm$ 10.7 (521)	0.58	18.6 $\pm$ 15.2 (371)	0.99	1.59 [1.41, 1.76]
MDS-UPDRS-III (no action tremor)	20	3.74 $\pm$ 4.92 (805)	5.27 $\pm$ 7.01 (722)	0.33	6.95 $\pm$ 8.93 (559)	0.40	9.6 $\pm$ 10.57 (408)	0.59	18.01 $\pm$ 15.37 (302)	0.97	1.73 [1.53, 1.93]
MDS-UPDRS-I+II+III	15	15.2 $\pm$ 12.0 (472)	17.7 $\pm$ 13.3 (413)	0.35	20.0 $\pm$ 14.8 (347)	0.39	24.9 $\pm$ 16.0 (230)	0.72	37.9 $\pm$ 24.3 (173)	1.20	2.81 [2.38, 3.23]
<b>Quantitative motor<sup>a</sup></b>											
Timed Up & Go (s)	2	8.04 $\pm$ 2.86 (346)	8.06 $\pm$ 2.67 (298)	0.08	8.17 $\pm$ 3.4 (243)	0.09	8.91 $\pm$ 6.58 (183)	0.19	9.05 $\pm$ 4.05 (141)	0.42	0.32 [0.15, 0.49]
Purdue Peg Board	2	10.59 $\pm$ 4.09 (271)	9.93 $\pm$ 3.51 (234)	-0.35	9.53 $\pm$ 3.98 (178)	-0.29	8.34 $\pm$ 3.6 (129)	-0.70	5.31 $\pm$ 4.86 (106)	-1.15	-0.81 [-0.98, -0.64]
<b>Autonomic<sup>a</sup></b>											
Postural Systolic Drop	6	10.1 $\pm$ 16.2 (383)	10.6 $\pm$ 15.6 (332)	0.08	11.9 $\pm$ 15.6 (259)	0.13	15.1 $\pm$ 16.4 (195)	0.22	18.9 $\pm$ 17.0 (149)	0.36	1.44 [1.01, 1.87]
SCOPA-AUT Total	10	10.95 $\pm$ 7.46 (213)	11.87 $\pm$ 7.86 (184)	0.13	12.03 $\pm$ 7.54 (140)	0.14	11.61 $\pm$ 6.81 (97)	0.11	14.04 $\pm$ 7.14 (57)	0.31	0.36 [0.05, 0.66]
<b>Olfactory</b>											
Olfaction z-score	14	-2.28 $\pm$ 1.8 (564)	-2.23 $\pm$ 1.84 (373)	-0.07	-2.29 $\pm$ 2.03 (287)	-0.07	-2.59 $\pm$ 2.07 (178)	-0.25	-3.39 $\pm$ 2.45 (139)	-0.64	-0.09 [-0.14, -0.05]
<b>Cognitive</b>											
MoCA	21	25.3 $\pm$ 3.2 (788)	25.4 $\pm$ 3.3 (694)	0.03	25.2 $\pm$ 3.6 (523)	0.01	24.8 $\pm$ 3.9 (388)	-0.08	24.1 $\pm$ 4.4 (273)	-0.22	-0.07 [-0.13, -0.01]
MMSE	15	27.7 $\pm$ 2.3 (706)	27.6 $\pm$ 2.3 (584)	-0.07	27.2 $\pm$ 2.8 (441)	-0.18	26.8 $\pm$ 3.1 (312)	-0.29	25.6 $\pm$ 3.7 (247)	-0.58	-0.25 [-0.32, -0.19]
<b>Psychiatric symptoms</b>											
Depression z-score	17	0.01 $\pm$ 0.98 (684)	0 $\pm$ 0.96 (562)	-0.02	0.01 $\pm$ 1.01 (437)	0.06	0.09 $\pm$ 0.99 (296)	0.11	0.13 $\pm$ 0.93 (199)	0.20	0.02 [0, 0.04]
Anxiety z-score	8	0.01 $\pm$ 1 (395)	0.01 $\pm$ 0.98 (316)	0.11	-0.04 $\pm$ 1.03 (257)	0.03	-0.07 $\pm$ 0.91 (190)	0.11	0.01 $\pm$ 1.03 (136)	0.18	0.02 [-0.01, 0.04]
<b>Sleep symptoms</b>											
ESS	11	6.76 $\pm$ 4.49 (583)	6.38 $\pm$ 4 (518)	-0.15	6.28 $\pm$ 4.18 (374)	-0.16	6.16 $\pm$ 4 (249)	-0.13	5.79 $\pm$ 4.21 (176)	-0.25	-0.25 [-0.33, -0.16]
ISI	5	9.29 $\pm$ 6.35 (310)	8.07 $\pm$ 5.44 (271)	-0.27	8.25 $\pm$ 5.86 (181)	-0.19	8.01 $\pm$ 5.29 (133)	-0.33	6.73 $\pm$ 5.99 (107)	-0.52	-0.61 [-0.78, -0.43]
PSQI	2	7.14 $\pm$ 4.01 (162)	6.54 $\pm$ 3.49 (154)	-0.15	7.15 $\pm$ 3.47 (94)	0.07	6.56 $\pm$ 2.88 (52)	-0.10	8.02 $\pm$ 3.45 (28)	0.14	-0.01 [-0.22, 0.2]
RBDSQ	5	9.43 $\pm$ 2.56 (247)	9.26 $\pm$ 2.57 (225)	-0.05	9.28 $\pm$ 2.76 (184)	-0.05	9.18 $\pm$ 2.93 (113)	-0.16	9.23 $\pm$ 2.8 (67)	-0.17	-0.09 [-0.2, 0.02]

2 The progression of variables of interest are described using annual mean  $\pm$  SD, standardized response mean (SRM), and estimated annual  
3 progression rate by LMEM. ESS=Epworth Sleepiness Scale; ISI=Insomnia Severity Index; MMSE=Mini-Mental State Examination;  
4 MoCA=Montreal Cognitive Assessment; PSQI=Pittsburgh Sleep Quality Inventory; RBDSQ=REM Behavior Disorder Sleep Questionnaire;  
5 SCOPA-AUT= Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction.

6 <sup>a</sup>Full results that include all clinical markers and 4-year follow-up data can be found in **Supplementary Table 4**.

7

1 **Table 3 Estimated progression rates subdivided by phenoconversion state**

	Total Cohort	Still Unconverted	PD	DLB	p-value	
Variable of interest	Estimate [95% CI]	Estimate [95% CI]	Estimate [95% CI]	Estimate [95% CI]	Unconverted vs. Phenoconverted	PD- vs DLB-phenoconverted
<b>MDS-UPDRS</b>						
MDS-UPDRS-I	0.48 [0.34, 0.61]	0.22 [0.11, 0.33]	0.95 [0.76, 1.13]	1.13 [0.9, 1.36]	<0.001	0.192
MDS-UPDRS-II	0.65 [0.55, 0.75]	0.26 [0.2, 0.31]	1.6 [1.46, 1.74]	1.38 [1.23, 1.53]	<0.001	0.037
MDS-UPDRS-III	1.59 [1.41, 1.76]	0.59 [0.51, 0.67]	4.41 [4.15, 4.66]	3.86 [3.56, 4.17]	<0.001	0.008
MDS-UPDRS-III (no action tremor)	1.73 [1.53, 1.93]	0.61 [0.52, 0.71]	4.44 [4.15, 4.73]	4.02 [3.69, 4.36]	<0.001	0.070
MDS-UPDRS-I+II+III	2.81 [2.38, 3.23]	1.47 [1.24, 1.7]	7.68 [6.99, 8.36]	6.75 [6.12, 7.38]	<0.001	0.082
<b>Quantitative Motor</b>						
Timed Up & Go (s)	0.32 [0.15, 0.49]	0.18 [0.07, 0.29]	0.44 [0.36, 0.52]	0.75 [0.41, 1.08]	<0.001	0.069
Timed Up & Go (m/s)	-0.02 [-0.02, -0.01]	-0.01 [-0.02, -0.01]	-0.04 [-0.04, -0.03]	-0.04 [-0.05, -0.03]	<0.001	0.221
Purdue Peg Board	-0.81 [-0.98, -0.64]	-0.64 [-0.77, -0.51]	-1.95 [-2.2, -1.7]	-1.59 [-1.86, -1.32]	<0.001	0.100
<b>Autonomic<sup>a</sup></b>						
Postural Systolic Drop	1.44 [1.01, 1.87]	1.02 [0.56, 1.48]	2.05 [1.3, 2.81]	2.38 [1.65, 3.11]	0.002	0.553
Postural Diastolic Drop	0.79 [0.48, 1.11]	0.59 [0.28, 0.9]	1.07 [0.6, 1.54]	1.35 [0.75, 1.96]	0.020	0.405
SCOPA-AUT Total	0.36 [0.05, 0.66]	0.20 [-0.06, 0.46]	0.15 [-0.25, 0.54]	1.57 [0.97, 2.23]	0.073	<0.001
<b>Olfactory</b>						
Olfaction z-score	-0.09 [-0.14, -0.05]	-0.06 [-0.1, -0.02]	-0.28 [-0.36, -0.2]	-0.28 [-0.36, -0.20]	<0.001	0.958
<b>Cognitive</b>						
MoCA	-0.07 [-0.13, -0.01]	0.06 [0.01, 0.11]	-0.09 [-0.18, -0.01]	-0.73 [-0.87, -0.59]	<0.001	<0.001
MMSE	-0.25 [-0.32, -0.19]	-0.09 [-0.14, -0.04]	-0.42 [-0.49, -0.36]	-0.81 [-0.91, -0.7]	<0.001	<0.001
<b>Psychiatric symptoms</b>						
Depression z-score	0.02 [0, 0.04]	0.02 [0, 0.04]	0.04 [0.02, 0.07]	0.04 [-0.02, 0.09]	0.100	0.854
Anxiety z-score	0.02 [-0.01, 0.04]	0.02 [0, 0.04]	0.01 [-0.03, 0.05]	0.04 [-0.01, 0.1]	0.981	0.504
<b>Sleep Symptoms</b>						
ESS	-0.25 [-0.33, -0.16]	-0.22 [-0.29, -0.14]	-0.19 [-0.31, -0.06]	-0.19 [-0.4, 0.02]	0.643	0.978
ISI	-0.61 [-0.78, -0.43]	-0.43 [-0.6, -0.25]	-0.77 [-1.05, -0.5]	-0.99 [-1.35, -0.64]	0.006	0.314
PSQI	-0.01 [-0.22, 0.2]	-0.03 [-0.24, 0.17]	0.28 [-0.05, 0.62]	0.22 [-0.17, 0.6]	0.058	0.712
RBDSQ	-0.09 [-0.2, 0.02]	-0.07 [-0.16, 0.01]	0.06 [-0.07, 0.2]	-0.14 [-0.26, -0.03]	0.394	0.136

2 Progression is described using estimated annual progression rate by LMEM. p-values were obtained by likelihood ratio tests of the full model  
3 with the interaction term against the model without the interaction term. ESS=Epworth Sleepiness Scale; ISI=Insomnia Severity Index;  
4 MMSE=Mini-Mental State Examination; MoCA=Montreal Cognitive Assessment; PSQI=Pittsburgh Sleep Quality Inventory; RBDSQ=REM  
5 Behavior Disorder Sleep Questionnaire; SCOPA-AUT= Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction. \*Results of all  
6 autonomic symptoms/signs can be found in **Supplementary Table 5**.



7



1 **Table 4** Calculated sample size estimates to detect differences in marker progression at 50% and 30% drug efficacy


	50% Drug Effectiveness Sample size per group		30% Drug Effectiveness Sample size per group	
	2-year study	3-year study	2-year study	3-year study
<b>Continuous Variable Analysis</b>				
MDS-UPDRS-I	657	445	1825	1236
MDS-UPDRS-II	355	255	986	708
MDS-UPDRS-III	244	175	678	486
MDS-UPDRS-III (without action tremor)	213	153	592	425
MDS-UPDRS-I+II+III	183	141	507	392
Timed Up & Go (s)	1496	1123	1013	10678
Timed Up & Go (m/s)	560	319	1556	886
Purdue Pegboard	151	98	419	272
Postural Systolic Drop	1026	453	2850	1258
SCOPA-Total	2459	1448	6831	4022
Olfaction z-score	2046	1076	5683	2989
MoCA	22007	12930	61131	35917
MMSE	870	612	2417	1700
Depression z-score	7404	3802	20567	10561
Anxiety z-score	11398	6601	31661	18336
<b>Event-based Analysis (time to event)</b>				
Purdue Pegboard increase $\geq 4$	273	164	896	540
MDS-UPDRS-III increase $\geq 4$	167	108	551	362
MoCA decrease $\leq 3$	497	304	1622	997
MDS-UPDRS-III $\geq 4$ or MoCA $\leq 3$	117	88	389	294
MDS-UPDRS I+II+III $\geq 12$	226	121	742	403
Phenoconversion	409	265	1337	869

2 Sample sizes for a 2-arm parallel trial in which treatment is expected to reduce the rate of progression by a constant amount throughout  
3 follow-up. Presented are required sample sizes to detect 30% or 50% treatment effects for a 2- or 3-year trial with periodic 6 month-follow-up  
4 (for continuous variable analysis) specifying 80% power and 2-sided alpha=0.05. Sleep symptoms are not included since scores paradoxically  
5 improved over time. MMSE=Mini-Mental State Examination; MoCA=Montreal Cognitive Assessment; SCOPA-AUT= Scales for Outcomes in  
6 Parkinson's Disease - Autonomic Dysfunction.  
7  
8



**Figure 1**  
165x64 mm (.46 x DPI)

1  
2  
3



1  
2  
3

Figure 2  
165x211 mm (.46 x DPI)




Figure 3  
165x184 mm (.46 x DPI)

1  
2  
3  
4




Figure 4  
165x222 mm (.46 x DPI)

1  
2  
3